PriceTargets.com logo

ANI Pharmaceuticals - ANIP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $77.71
  • Forecasted Upside: 45.67%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$53.35 As of 12/20/2024 06:31 PM ET
▼ -0.91 (-1.68%)

This chart shows the closing price for ANIP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ANI Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIP

Analyst Price Target is $77.71
▲ +45.67% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is $77.71, with a high forecast of $94.00 and a low forecast of $62.00. The average price target represents a 45.67% upside from the last price of $53.35.

This chart shows the closing price for ANIP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in ANI Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024Leerink PartnrsUpgradeStrong-Buy
12/11/2024Leerink PartnersInitiated CoverageOutperform$80.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00
10/22/2024Truist FinancialBoost TargetHold ➝ Hold$60.00 ➝ $62.00
10/11/2024Piper SandlerInitiated CoverageOverweight$68.00
9/18/2024Raymond JamesBoost TargetOutperform ➝ Outperform$81.00 ➝ $83.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00
9/11/2024Truist FinancialReiterated RatingBuy ➝ Hold$80.00 ➝ $60.00
8/7/2024Truist FinancialDowngradeStrong-Buy ➝ Hold
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00
6/26/2024HC WainwrightBoost TargetBuy ➝ Buy$87.00 ➝ $94.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$83.00 ➝ $87.00
4/23/2024GuggenheimReiterated RatingBuy ➝ Buy$77.00
3/15/2024Capital One FinancialInitiated CoverageOverweight$80.00
3/5/2024GuggenheimBoost TargetBuy ➝ Buy$70.00 ➝ $77.00
3/4/2024HC WainwrightBoost TargetBuy ➝ Buy$73.00 ➝ $83.00
3/1/2024Truist FinancialBoost TargetBuy ➝ Buy$72.00 ➝ $80.00
2/16/2024Truist FinancialBoost TargetBuy ➝ Buy$70.00 ➝ $72.00
10/19/2023GuggenheimReiterated RatingBuy ➝ Buy$72.00
9/13/2023GuggenheimReiterated RatingBuy ➝ Buy$72.00
8/22/2023HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $73.00
8/21/2023Truist FinancialReiterated RatingBuy ➝ Buy$70.00
8/10/2023GuggenheimBoost TargetBuy ➝ Buy$62.00 ➝ $72.00
7/27/2023GuggenheimBoost Target$59.00 ➝ $62.00
7/21/2023Truist FinancialBoost TargetBuy$52.00 ➝ $60.00
5/9/2023GuggenheimBoost Target$55.00 ➝ $59.00
5/9/2023HC WainwrightBoost Target$53.00 ➝ $60.00
3/13/2023HC WainwrightBoost TargetBuy$50.00 ➝ $53.00
2/28/2023GuggenheimInitiated CoverageBuy$55.00
2/21/2023HC WainwrightReiterated RatingBuy$50.00
9/7/2022HC WainwrightInitiated CoverageBuy$50.00
8/9/2022Raymond JamesBoost TargetOutperform$47.00 ➝ $48.00
3/16/2022Cantor FitzgeraldReiterated RatingNeutral
3/16/2022Raymond JamesLower TargetOutperform$65.00 ➝ $47.00
11/2/2021Truist FinancialInitiated CoverageBuy$70.00
11/2/2021Raymond JamesBoost TargetOutperform$60.00 ➝ $65.00
5/10/2021Raymond JamesBoost TargetOutperform$40.00 ➝ $60.00
8/3/2020Raymond JamesLower TargetOutperform$49.00 ➝ $40.00
5/8/2020Raymond JamesLower TargetOutperform$65.00 ➝ $49.00
5/7/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$78.00 ➝ $40.00
4/30/2020GuggenheimLower TargetBuy$62.00 ➝ $58.00
2/28/2020Raymond JamesLower TargetOutperform$75.00 ➝ $65.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.31 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 17 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 9 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 11 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 11 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ANI Pharmaceuticals logo
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Read More

Today's Range

Now: $53.35
Low: $53.00
High: $54.56

50 Day Range

MA: $57.93
Low: $53.88
High: $61.74

52 Week Range

Now: $53.35
Low: $52.00
High: $70.81

Volume

1,066,257 shs

Average Volume

225,876 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of ANI Pharmaceuticals?

The following equities research analysts have issued research reports on ANI Pharmaceuticals in the last twelve months: Capital One Financial Co., Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, Piper Sandler, Raymond James, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for ANIP.

What is the current price target for ANI Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ANI Pharmaceuticals in the last year. Their average twelve-month price target is $77.71, suggesting a possible upside of 45.7%. HC Wainwright has the highest price target set, predicting ANIP will reach $94.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $62.00 for ANI Pharmaceuticals in the next year.
View the latest price targets for ANIP.

What is the current consensus analyst rating for ANI Pharmaceuticals?

ANI Pharmaceuticals currently has 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIP will outperform the market and that investors should add to their positions of ANI Pharmaceuticals.
View the latest ratings for ANIP.

What other companies compete with ANI Pharmaceuticals?

Other companies that are similar to ANI Pharmaceuticals include Arcellx, ADMA Biologics, Ultragenyx Pharmaceutical, Apellis Pharmaceuticals and Biohaven. Learn More about companies similar to ANI Pharmaceuticals.

How do I contact ANI Pharmaceuticals' investor relations team?

ANI Pharmaceuticals' physical mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company's listed phone number is (218) 634-3500 and its investor relations email address is [email protected]. The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com. Learn More about contacing ANI Pharmaceuticals investor relations.